✦ LIBER ✦

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

✍ Scribed by Amit Mahipal; Mark Weiss

Book ID: 107546770
Publisher: Current Science Inc.
Year: 2010
Tongue: English
Weight: 80 KB
Volume: 12
Category: Article
ISSN: 1523-3790
DOI: 10.1007/s11912-010-0122-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolonged progression-free survival in p

Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab

✍ Michaela Gruber; Karin Fleiss; Edit Porpaczy; Cathrin Skrabs; Alexander W. Hausw 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 144 KB

The addition of rituximab to fludarabine

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

✍ Giovanni Del Poeta; Maria Ilaria Del Principe; Maria Antonietta Irno Consalvo; L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Chemoimmunotherapy with modified dosing

Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia

✍ Nicole Lamanna; Mark A. Weiss 📂 Article 📅 2009 🏛 Current Science Inc. 🌐 English ⚖ 164 KB

Circulating CD52 and CD20 levels at end

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

✍ Gheath Alatrash; Maher Albitar; Susan O’Brien; Xuemei Wang; Taghi Manshouri; Ste 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Consolidation with alemtuzumab improves

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

✍ Carmen D. Schweighofer; Matthias Ritgen; Barbara F. Eichhorst; Raymonde Busch; W 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB